Cannabis Linked to Larger Brain Volume in Older Adults, Major Study Finds
Advertisement
For decades, the dominant narrative around cannabis and the brain has been one of damage — shrinking hippocampi, impaired memory, cognitive decline. A major new study from the University of Colorado Anschutz Medical Campus is challenging that story with data from more than 26,000 adults, and the findings are turning heads in both the research community and the cannabis world. Published in the Journal of Studies on Alcohol and Drugs, the study found that lifetime cannabis use was associated with larger brain volumes in key regions and better cognitive performance in people aged 40 to 77.
Key Takeaways
- Moderate cannabis use showed the strongest positive associations for most measures, though heavy users outperformed on visual memory tasks.
- The study does not prove causation and does not apply to adolescents, but it challenges long-held assumptions about cannabis and brain health in older adults.
- A study of 26,362 adults aged 40–77 found that lifetime cannabis use was associated with larger brain volumes in CB1-rich regions including the hippocampus, caudate, and amygdala, and with better cognitive performance.
Table of Contents
- What the UK Biobank Data Revealed
- Dose Matters: The Moderate-Use Sweet Spot
- Why This Study Is Different
- The Endocannabinoid System [Quick Definition: Your body's built-in network of receptors that interact with cannabinoids] and Brain Aging
- What This Does Not Mean
- Implications for Aging, Medicine, and Policy
What the UK Biobank Data Revealed
The research team, led by clinical psychologist Anika Guha, PhD, analyzed data from the UK Biobank — one of the world's largest biomedical databases, containing health information from over 500,000 adults. The study focused on 26,362 participants with an average age of 55, examining the relationship between self-reported lifetime cannabis use, regional brain volume measured by MRI, and performance on standardized cognitive tests.
The results ran counter to conventional assumptions. Cannabis users showed larger brain volumes in several regions rich in CB1 cannabinoid receptors — the molecular targets that THC binds to. These included the caudate, putamen, hippocampus, and amygdala — all structures involved in memory, learning, emotional processing, and motor control.
On cognitive assessments, cannabis users outperformed non-users in areas including learning and memory, processing speed, attention, and executive function.
The hippocampus finding is particularly striking. This brain structure is central to memory formation and has been the focus of many previous studies suggesting cannabis causes damage. The UK Biobank data tell a different story — at least for adults in midlife and beyond.
Dose Matters: The Moderate-Use Sweet Spot
One of the study's most nuanced findings involves the relationship between dose and outcomes. The researchers divided participants into groups based on lifetime cannabis use levels and found that the picture was not simply "more cannabis, better brain."
For most brain regions and cognitive measures, the moderate-use group showed the best outcomes — larger volumes and stronger cognitive performance compared to both non-users and heavy users. However, there were notable exceptions. The high-use group actually demonstrated the best results on visual memory and learning tasks and had the largest right amygdala volumes.
In one area, higher use showed a potential downside: the posterior cingulate cortex, a region involved in self-referential thought and memory retrieval, showed lower volumes in the highest-use group. This suggests the effects of cannabis on brain structure are not uniform across all regions.
"The story is nuanced," Guha said. "It's not a case of cannabis being all good or all bad. It depends on how people are using and what outcomes you're looking at."
Why This Study Is Different
Cannabis brain research has historically relied on small sample sizes, young adult populations, and cross-sectional designs that make it difficult to separate cause from correlation. The UK Biobank study addresses several of these limitations simultaneously.
The sample size of more than 26,000 participants gives the study statistical power that smaller studies simply cannot match. By focusing on adults aged 40 to 77, the research fills a critical gap — most cannabis neuroscience has concentrated on adolescents and young adults, leaving the effects on the aging brain largely unexplored. And while the study is still observational (meaning it cannot prove causation), its scale and the quality of the UK Biobank data set it apart from earlier work.
The focus on CB1-rich brain regions was also methodologically deliberate. Rather than looking at the brain as a whole, the researchers targeted structures where cannabinoid receptors are most concentrated, reasoning that these areas would show the clearest signal of any cannabis-related effects.
The Endocannabinoid System and Brain Aging
The findings raise questions about the role of the endocannabinoid system (ECS) in brain aging. The ECS — a network of receptors, enzymes, and endogenous cannabinoids found throughout the body — plays a role in regulating mood, memory, appetite, and neuroinflammation. Research in animal models has shown that the ECS becomes less active with age, and some scientists have hypothesized that supplementing it with plant-derived cannabinoids could have neuroprotective effects.
A 2017 study from the University of Bonn found that low doses of THC improved memory and learning in older mice, while impairing younger ones — a finding that aligns with the pattern seen in the UK Biobank data, where the benefits of cannabis use appeared specifically in an older population.
If the ECS does become depleted with age, moderate cannabis use could theoretically help restore signaling in brain regions that depend on it. This is speculative territory, and the CU Anschutz researchers are careful not to overstate their conclusions, but the data provide a credible foundation for further investigation.
What This Does Not Mean
It would be a mistake to interpret this study as a blanket endorsement of cannabis use for brain health. The researchers explicitly note several caveats. The UK Biobank population skews toward healthier, more educated, and predominantly white participants, which limits generalizability.
Self-reported cannabis use data may be subject to recall bias. And because the study is cross-sectional, it's possible that people with naturally larger brain volumes or better cognition were simply more likely to use cannabis — a classic chicken-and-egg problem.
The study also does not address cannabis use in adolescence, where the evidence for potential harm remains more consistent. Brain development continues into the mid-twenties, and the effects of cannabis on a developing brain may be fundamentally different from its effects on an aging one.
Implications for Aging, Medicine, and Policy
Despite these caveats, the study adds meaningful data to a conversation that has been dominated by assumptions rather than evidence — particularly when it comes to older adults. With cannabis use among Americans over 45 growing faster than any other demographic (a trend Budpedia has covered extensively), research that examines outcomes in this specific population is not just relevant but urgent.
For the medical cannabis community, the findings support continued investigation into cannabinoids as potential interventions for age-related cognitive decline and neurodegenerative conditions. Several clinical trials exploring cannabis-based treatments for Alzheimer's disease, Parkinson's disease, and traumatic brain injury are already underway at institutions including the University of California, San Diego.
For policymakers, the data complicate simplistic narratives about cannabis and brain damage — narratives that have historically been used to justify prohibition. That does not mean regulation is unnecessary, but it does suggest that evidence-based policy should account for the growing body of research showing that the relationship between cannabis and the brain is far more complex than "your brain on drugs" suggested.
Pull-Quote Suggestions:
"The UK Biobank data tell a different story — at least for adults in midlife and beyond."
"The UK Biobank study addresses several of these limitations simultaneously."
"The UK Biobank population skews toward healthier, more educated, and predominantly white participants, which limits generalizability."
Why It Matters: A UK Biobank study of 26,000+ adults finds cannabis use linked to larger brain volumes and better cognition in people over 40. Here's what the data shows.